28th week of 2014 patent applcation highlights part 45 |
Patent application number | Title | Published |
20140194330 | Lubricating Composition Containing an Ester of an Aromatic Carboxylic Acid - The invention provides a lubricating composition containing an oil of lubricating viscosity and an ester, thioester, amide or imide of a carboxylic acid compound where said carboxylic acid is characterized in that it is functionalized with a hydroxy-substituted aromatic moiety. The invention further relates to methods of lubricating an internal combustion engine by supplying the described lubricating composition to the internal combustion engine. The invention further relates to the use of the salt of the carboxylic acid compound as an antiwear agent or an antioxidant. | 2014-07-10 |
20140194331 | HIGH PERFORMANCE BIOHYDRAULIC FLUID - A biohydraulic fluid which has high performance attributes and which is environmentally acceptable includes trimethylolpropane (TMP) esterified to monounsaturated fatty acids of unsaturated vegetable oils or vegetable oil blends. The process for making the TMP esters can be accomplished in a manner similar to biodiesel production wherein methyl oleates obtained from reacting methanol with the vegetable oils or vegetable oil blends are reacted with TMP. Production of the TMP esters can be achieved without the use of catalysts. | 2014-07-10 |
20140194332 | TWO-PHASE LUBRICATING OIL COMPOSITION - Lubricating oil compositions are provided herein that comprise a mixture of: (A) a hydrocarbon as a low-viscosity constituent, (B) a polyalkylene glycol (PAG) as a high-viscosity constituent wherein the oxygen/carbon weight ratio is in the range of from 0.450 to 0.580, and (C) a compound as a control constituent wherein the oxygen/carbon weight ratio is in the range of from 0.080 to 0.350. Methods of lubricating a surface using such lubricating compositions are also provided herein. | 2014-07-10 |
20140194333 | METHOD FOR IMPROVING ENGINE FUEL EFFICIENCY - A method for improving fuel efficiency, while maintaining or improving high temperature wear, deposit and varnish control, in an engine lubricated with a lubricating oil by using as the lubricating oil a formulated oil. The formulated oil has a composition including a lubricating oil base stock as a major component, and at least one alkoxylated alcohol as a minor component. Fuel efficiency is improved and high temperature wear, deposit and varnish control are maintained or improved as compared to high temperature wear, deposit and varnish control achieved using a lubricating engine oil containing a minor component other than the at least one alkoxylated alcohol. A lubricating engine oil having a composition including a lubricating oil base stock as a major component, and at least one alkoxylated alcohol as a minor component. The lubricating engine oils are useful in internal combustion engines including direct injection, gasoline and diesel engines. | 2014-07-10 |
20140194334 | Detergent Composition - A detergent composition excellent in an antimicrobial activity. Thus, a detergent composition of the present invention is characterized by including:
| 2014-07-10 |
20140194335 | COMPOSITIONS AND METHODS FOR TREATING BIOFILMS - Compositions and methods for treating biofilm formation and growth on a substrate are provided. The composition comprises 1 ppb to 1,000 ppm of at least one D-amino acid and 1 ppm to 60,000 ppm of at least one biocide. The method comprises contacting the substrate with 1 ppb to 1,000 ppm of at least one D-amino acid and 1 ppm to 60,000 ppm of at least one biocide. The compositions and methods are effective for preventing, reducing or eliminating biofilm formation or biofilm growth or both, as well as eradicating established, recalcitrant biofilms, particularly biofilms comprising sulfate reducing bacteria that are known to cause microbiologically influenced corrosion, biofouling, or both. | 2014-07-10 |
20140194336 | SOPHOROLACTONE PRODUCTION - The present invention relates to a process for selectively producing sophorolactone without use of organic solvent, comprising the steps of: -pre-cultivating cells of a | 2014-07-10 |
20140194337 | EMULSION COMPOSITIONS AND A METHOD FOR SELECTING SURFACTANTS - A method for preparing a microemulsion is disclosed which employs a method based upon identification of the phase behavior of a plurality of components comprising the microemulsion. Further disclosed is a microemulsion composition comprising a first component, coupling agent, and surfactant. | 2014-07-10 |
20140194338 | Fragrance Compositions - A fragrance composition and use thereof by inhalation to promote activated, pleasant moods. The fragrance composition comprises at least 75% by weight of perfume materials including at least 10% by weight of at least three specific materials from a group identified as Group IMP and optionally up to 90% of specific materials selected from groups identified as HMR, HMI, HMP, RMP and GEN, the amounts of materials from said Groups falling within specified relationships. | 2014-07-10 |
20140194339 | NOVEL QUINAZOLINE COMPOUNDS AND THEIR USE IN PERFUME COMPOSITIONS - The present invention relates to novel quinazoline compounds and their use in perfume compositions. The novel quinazoline compounds of the present invention are represented by the following formula: | 2014-07-10 |
20140194340 | DIAGNOSING, MONITORING AND TREATING INFLAMMATION - The present invention provides methods and compositions for treating chronic inflammatory disease in a subject and associated pharmaceutical compositions, medical devices and systems. | 2014-07-10 |
20140194341 | Silica Compositions - Compositions are provided, the compositions comprising: a silica compound containing at least one nitrogen atom; and a carboxylated polymer containing at least one nitrogen atom. The compositions may be useful to control algal growth, including harmful algal blooms (HAB). | 2014-07-10 |
20140194342 | Peptide-Based Peroxidase Inhibitors and Methods of Using Same - The present invention provides peptide-based peroxidase inhibitors having the formula AA | 2014-07-10 |
20140194343 | CTRP6 WHICH CAN BE USED AS THERAPEUTIC AND PROPHYLACTIC AGENT FOR AUTOIMMUNE DISEASES - [Problem] The topic of the present invention is the elucidation of the biological function of CTRP6 and its application. | 2014-07-10 |
20140194344 | FUSION PEPTIDE DESIGNED TO REDUCE PLAQUE BACTERIA AND YEAST IN THE ORAL CAVITY - The present invention relates generally to dental diseases, caries and periodontal disease. More specifically, the invention relates to Lactoferrin and PAK fusion peptides (PAK-LF), along with therapeutic, diagnostic and research uses for these polypeptides. The present invention also provides methods of treating dental diseases, caries and periodontal disease. | 2014-07-10 |
20140194345 | NOVEL DEPSIPEPTIDE AND USES THEREOF - The present invention relates generally to novel depsipeptides, to methods for the preparation of these novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders. | 2014-07-10 |
20140194346 | PASTEURELLACEAE VACCINES - The present invention relates to an N-glycosylated protein for treating and/or preventing bacterial Pasteurellaceae infection in a mammal or bird, wherein the protein is a Pasteurellaceae protein, a functional fragment or derivative thereof having at least one glycosylated N-X-S/T consensus sequence. In addition, the present invention is directed to corresponding pharmaceutical compositions for treating and/or protecting mammals or birds having or being prone to develop a bacterial Pasteurellaceae infection. Furthermore, the invention describes methods for producing said N-glycosylated proteins. | 2014-07-10 |
20140194347 | INFLUENZA INHIBITING COMPOSITIONS AND METHODS - The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (FIR) of a wild-type influenza hemagglutinin 2 protein or a variant thereof. In a preferred embodiment, a peptide of the invention consists of 8 to 40 consecutive amino acid residues a portion of a wild-type influenza hemagglutinin 2 protein or a variant thereof, the portion of the protein comprising the FIR of the protein and up to five amino acid residues on the amino-terminal and carboxy-terminal sides of the FIR. | 2014-07-10 |
20140194348 | METHOD OF INHIBITING PAPILLOMAVIRUS PROLIFERATION AND TREATING PAPILLOMAVIRUS INFECTION - Methods for inhibiting virus proliferation and treating an individual having a papillomavirus infection preventing viral infection are disclosed. The methods include the steps of providing a composition comprising a plurality of papillomavirus virus-like particles or capsomeres and contacting papillomavirus-infected tissue of an individual with the composition under conditions effective to inhibit papillomavirus proliferation or treat the papillomavirus infection in the individual. | 2014-07-10 |
20140194349 | HIV Protease Inhibiting Compounds - A compound of the formula | 2014-07-10 |
20140194350 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS - The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2014-07-10 |
20140194351 | Hemipteran-and Coleopteran Active Toxin Proteins from Bacillus Thuringiensis | 2014-07-10 |
20140194352 | Compositions and Methods for Treatment of Metabolic Disorders and Diseases - The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders. | 2014-07-10 |
20140194353 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NERVOUS DISORDERS ASSOCIATED WITH DIABETES - Compositions and methods for treating neural dysfunction. A exemplary method comprises administering to a subject having a neuropathy, e.g., a cognitive dysfunction or Alzheimer's, a therapeutically effective amount of an insulin or insulin analog, wherein the insulin or insulin analog crosses the BBB and/or a compound that increases SREBP-2 expression or activity in the CNS of the subject. | 2014-07-10 |
20140194354 | Methods for Treatment of Nephrotic Syndrome and Related Conditions - The present disclosure provides a method for treating and/or preventing nephrotic syndrome, such as but not limited to minimal change disease and membranous nephropathy, and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein. Such methods comprise the therapeutic delivery of an Angptl4 polypeptide or Angptl4 polypeptide derivative to a subject. | 2014-07-10 |
20140194355 | Isolated Nucleic Acid Molecules Encoding Variant Activin Receptor Polypeptides - The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided. | 2014-07-10 |
20140194356 | AQUEOUS FORMULATION COMPRISING AT LEAST A NEUTRAL SALT AND A BIOPHARMACEUTICAL PROTEIN - The present invention is related to a pharmaceutically acceptable aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein, wherein the concentration ratio between the biopharmaceutical protein and the neutral salt is in the range of ≧0.7 and ≦5. | 2014-07-10 |
20140194357 | Modified Relaxin Polypeptides and Their Uses - Modified relaxin polypeptides and their uses thereof are provided | 2014-07-10 |
20140194358 | PROMININ-1 PEPTIDE FRAGMENTS AND USES THEREOF - Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration. | 2014-07-10 |
20140194359 | INTERFERING RNA DELIVERY SYSTEM AND USES THEREOF - The invention provides a delivery system comprising a cell penetrating peptide, 10 histidines, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided. | 2014-07-10 |
20140194360 | USE OF ANTITHROMBIN IN EXTRACORPOREAL MEMBRANE OXYGENATION - In one aspect, the disclosure provides methods of suppressing blood clotting and/or preventing hemorrhage in a subject having extracorporeal membrane oxygenation comprising administering antithrombin. In some embodiments, the antithrombin used in the methods disclosed herein is ATryn®. | 2014-07-10 |
20140194361 | Vault Agents for Treating Chronic Kidney Disease - The invention relates to compositions of vault complexes containing cell adhesion inhibiting agents, such as a RGD-peptide, and methods of using the vault complexes in the treatment of diseases, such as chronic kidney disease. | 2014-07-10 |
20140194362 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof - The present invention provides a novel class of macrocyclic compounds, which are useful as cysteine protease inhibitors. Also provided are novel intermediates and methods of preparing the compounds. The invention also provides pharmaceutical compositions comprising the compounds. The compounds and compositions are useful in methods of treating or preventing one or more diseases associated with cysteine protease activity, particularly those associated with calpain activity. | 2014-07-10 |
20140194363 | Compression-resistant collagen-based artificial bone repair material - The present invention provides a compression-resistant collagen-based artificial bone repair material that could be used for bone defect repair at human load-bearing sites. Such material has a composition and structure of self-assembled nano-sized calcium phosphate salt and collagen molecules, thereby possessing a biomimetic mineralization structure similar to the natural bone. On the aspect of mechanical properties, such material has a similar mechanical strength to human cortical bone, which makes it suitable for repairing bone defects at human load-bearing sites. The present invention further provides preparation methods of such Compression-resistant collagen-based artificial bone repair material. | 2014-07-10 |
20140194364 | Biomarkers for Painful Intervertebral Discs and Methods of Use Thereof - The present disclosure provides methods of diagnosing painful intervertebral discs. The present disclosure also provides methods of treating a painful intervertebral disc. | 2014-07-10 |
20140194365 | USE OF ENDOSTATIN PEPTIDES FOR THE TREATMENT OF FIBROSIS - C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung. | 2014-07-10 |
20140194366 | OVARIAN CANCER STEM CELLS AND METHODS OF ISOLATION AND USES THEREOF - The present invention generally relates to methods, assays, compositions and kits related to a subpopulation of ovarian cancer stem cells which are selected or enriched by chemotherapeutic agents and inhibited by MIS (Mullerian Inhibiting Substance) and MIS mimetics. In particular, the present invention relates to a population of CD44+/CD24+/EpCam+/ECad− subpopulation of ovarian cancer stem cells. The present invention also provides methods to screen a subject with ovarian cancer to identify if they have an ovarian cancer comprising CD44+/CD24+/EpCam+/ECad− ovarian cancer stem cells, and methods to identify and enrich or isolate for such ovarian cancer cell populations. | 2014-07-10 |
20140194367 | AGROCYBE AEGERITA LECTIN AAL-2, AND ENCODING GENE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF - The isolated | 2014-07-10 |
20140194368 | Method of Treating Cancer by Administration of Low Levels of Heat Shock Protein 70 (HSP70) - The invention is directed to methods of treating cancer by administration of heat shock protein 70 (Hsp70) to the subject suffering from cancer. | 2014-07-10 |
20140194369 | CYCLIC LACTADHERIN PEPTIDE MIMETICS AND THEIR USES - Provided herein is a new class of cyclic lactadherin peptides (cLac) that mimic the natural phosphatidylserine (PS)-binding activity of the parent lactadherin protein. These cLacs are useful as small molecule indicators of early stage of apoptosis and of treatment efficacy evaluation. | 2014-07-10 |
20140194370 | SILK-ELASTIN LIKE PROTEIN POLYMERS FOR EMBOLIZATION AND CHEMOEMBOLIZATION TO TREAT CANCER - A chemoembolic agent is disclosed that includes an injectable, recombinantly synthesized silk-elastin like protein copolymer and one or more chemotherapeutic agents. Upon injection, the chemoembolic agent blocks the tumor vasculature, including the capillary bed, and may optionally release chemotherapeutic agents. The chemoembolic agent may be used to treat cancer, including hepatocellular carcinoma. | 2014-07-10 |
20140194371 | SOLID OXIDIZED GLUTATHIONE SALT AND METHOD FOR PRODUCING SAME - A solid oxidized glutathione salt is produced by heating an oxidized glutathione at 30° C. or higher while the oxidized glutathione is brought into contact with an aqueous medium in the presence of a substance for providing a cation, to produce the salt of the oxidized glutathione and the cation as a solid, wherein the aqueous medium is composed of water and/or a water-soluble medium, and the cation is at least one selected from an ammonium cation, a calcium cation and a magnesium cation. | 2014-07-10 |
20140194372 | HEART FAILURE SUPPRESSING AGENT - Provided are a medicine and a food product that suppress a heart disease such as cardiomegaly and heart failure. Specifically provided is an agent for suppressing a heart disease selected from heart failure, cardiac fibrosis, ventricular wall thickening and cardiomegaly, which comprises luteolin or a derivative thereof as an active ingredient. | 2014-07-10 |
20140194373 | COSMETIC USE OF HESPERIDIN OR A DERIVATIVE THEREOF IN THE PREVENTION AND/OR TREATMENT OF BODY ODOUR - The present invention relates to the cosmetic use, in particular the oral use, of at least an effective amount of hesperidin or a derivative thereof as a deodorant agent. | 2014-07-10 |
20140194374 | Anthelmintic Formulations and Treatments - A new method of controlling worm burden in ruminants by using two different injectable anthelmintics at or about the same time to increase the time between treatments and to rely on the animal's immune response. One of the anthelmintics is a long acting formulation capable of providing a sustained release of abamectin or other macrocyclic lactone for 2-14 days, to enable the anthelmintic to remove or kill incoming larvae for a sufficiently long period of time to allow the host to recognise the incoming larvae as foreign, and thus allow the ruminant to mount an immune response against these incoming larvae. The other is a short acting anthelmintic such as levamisole designed to substantially eliminate the initial parasite population of adults, juveniles and larvae. They can be combined into a single injectable formulation with a high percentage of levamisole (preferably over 30% of the formulation w/v) together with about 1% w/v of a macrocyclic lactone such as abamectin, dissolved in glycerol formal. | 2014-07-10 |
20140194375 | TOPICAL ANTIBIOTIC COMPOSITION FOR THE PREVENTION OF LYME DISEASE - The invention relates to topical pharmaceutical compositions and methods related to | 2014-07-10 |
20140194376 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS - The present invention provides compounds of formula (I) wherein G | 2014-07-10 |
20140194377 | Salts of Isophosphoramide Mustard and Analogs Thereof - Disclosed herein are crystalline compounds of formula (I) | 2014-07-10 |
20140194378 | Methods of Preventing or Treating Diseases and Conditions Using Complex Carbohydrates - The invention relates to a method of preventing and treating diseases and conditions associated with allergies, autoimmunity, the adhesion cascade, the metastatic cascade or the coronary cascade comprising administering (i) at least one complex carbohydrate as the sole active ingredient, or (ii) at least one pharmaceutical composition which comprises as an active ingredient a pharmacologically effective amount of at least one low purity or cosmetic grade complex carbohydrate selected from the group consisting of oligosaccharides, sialylated oligosaccharides, polysaccharides and glycosaminoglycans, and an effective amount of at least one transdermal or transmucosal carrier in an amount effective to deliver the complex carbohydrate into the blood stream. | 2014-07-10 |
20140194379 | METHODS FOR THE PRODUCTION OF CHITIN NANOFIBERS AND USES THEREOF - Methods for the production chitin nanofibers and uses thereof. Furthermore, methods for the production of chitin nanofibers and the fabrication of chitin nanofiber structures and devices. | 2014-07-10 |
20140194380 | METHOD OF MANUFACTURING COMPOSITION COMPRISING LOCAL ANESTHETIC, HEPARINOID, AND BUFFER - An improved method for preparing a composition including a heparinoid, a local anesthetic, and a buffer for treatment of a lower urinary tract disease or condition can comprise either: (A) (i) providing a heparinoid in solid form or liquid form; (ii) providing a local anesthetic in solid form or liquid form; (iii) adding a liquid buffer to the heparinoid in solid form or liquid form; (iv) adding the local anesthetic to the mixture of the liquid buffer and the heparinoid; and (v) if necessary, adjusting the pH of the mixture of the liquid buffer, the local anesthetic, and the heparinoid so that a pH is achieved of from about 6.8 to about 8.3 is achieved without precipitation of the local anesthetic; or (B) (i)providing a heparinoid in solid form or liquid form; (ii) providing a local anesthetic in solid form or liquid form; (iii) mixing the heparinoid in solid form or liquid form and the local anesthetic in solid form or liquid form; (iv) adding a liquid buffer to the mixture of the heparinoid and the local anesthetic to form a mixture of liquid buffer, the heparinoid, and the local anesthetic; and (v) if necessary, adjusting the pH of the mixture of the liquid buffer, the local anesthetic, and the heparinoid so that a pH is achieved of from about 7.0 to about 7.8 is achieved without precipitation of the local anesthetic. The invention also encompasses a stable premixed liquid composition that avoids precipitation of the local anesthetic. | 2014-07-10 |
20140194381 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF - Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents. | 2014-07-10 |
20140194382 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF - Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents. | 2014-07-10 |
20140194383 | MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME - Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins. | 2014-07-10 |
20140194384 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF - Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents. | 2014-07-10 |
20140194385 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF - Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents. Other embodiments relate to pharmaceutical compositions containing boronic acid derivatives and additional excipient such as meglumine. | 2014-07-10 |
20140194386 | BETA-LACTAMASE INHIBITORS - Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections. | 2014-07-10 |
20140194387 | DERIVATIVES OF 1-AMINO-2-CYCLOBUTYLETHYLBORONIC ACID - The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. | 2014-07-10 |
20140194388 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS - A pharmaceutical composition comprising a CHK inhibitor, and an Hsp90 inhibitor according to the following formulae or tautomers, or pharmaceutically acceptable salts thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof, using pharmaceutical compositions described herein. | 2014-07-10 |
20140194389 | BISPHOSPHONATE COMPOUNDS - Novel bisphosphonate cyclic acetal compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating bone metabolism disorders, such as abnormal calcium and phosphate metabolism. | 2014-07-10 |
20140194390 | PESTICIDAL COMPOSITIONS - A method of controlling pest with a pesticidal composition comprising synergistically effective amounts of at least one anthranilamide compound represented by the formula (I) or its salt and other pesticide: | 2014-07-10 |
20140194391 | CALCIUM/SODIUM SALT OF INOSITOL TRIPYROPHOSPHATE AS AN ALLOSTERIC EFFECTOR OF HEMOGLOBIN - The present invention relates to mixed calcium/sodium salt of inositol tripyrophosphate, methods of preparing and methods of use. The mixed calcium/sodium salt may be a monocalcium tetrasodium salt of inositol tripyrophosphate. Methods of use include administering the above salts in an effective amount to treat diseases caused by hypoxia or other conditions associated with inadequate function of the lungs or circulatory system, such as various types of cancer and Alzheimer's disease. | 2014-07-10 |
20140194392 | DRUG SCREENING METHOD - A drug screening method is disclosed. The drug screening method includes steps of screening a compound library to obtain a first group of compounds capable of binding to a wild type target; screening the first group of compounds to obtain a second group of compounds capable of binding to a mutant site of a mutant target; analyzing characteristics of binding sites of the wild type target and the mutant type target to obtain physico-chemical properties of the binding sites; identifying a candidate from the second group of compounds according to the physico-chemical properties of the binding site; and performing a bio-assay on inhibitory activity of the candidate. | 2014-07-10 |
20140194393 | TETRACYCLINE COMPOSITIONS - The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation. | 2014-07-10 |
20140194394 | TWO-COMPONENT FORMULATIONS, METHODS AND PROCEDURES TO PREVENT OR REDUCE TRAUMA-INDUCED NEUROPATHOLOGY AND NEURODEGENERATION - Novel two-component formulations, procedures and methods for use in treating neuropathology incident to trauma are provided. Two-component formulations of the invention comprise biologically active forms of at least one neurosteroid or neuroactive steroid, such as progesterone or synthetic progestin, and at least one anti-epileptic or anticonvulsant, such as gabapentin. The provided formulations are configured or adapted to prevent or reduce the incidence and severity of neurological damage caused by trauma. Formulations, procedures and methods of the invention advantageously effect both neuroprotective actions to prevent or reduce secondary injuries, and neurotrophic actions to repair and restore cells and tissues affected by the trauma, and are especially useful in treating neurological trauma, such as those caused by sports injuries, chemical weapons, vehicle collisions and improvised explosive devices in combat. | 2014-07-10 |
20140194395 | COMPOSITIONS AND METHODS FOR TREATING CENTRALLY MEDIATED NAUSEA AND VOMITING - Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery. | 2014-07-10 |
20140194396 | ORGANIC COMPOUNDS - The present invention relates to PDEI inhibitory compounds of Formula I as described herein, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them. | 2014-07-10 |
20140194397 | MULTIPLE-COMPONENT PHARMACEUTICAL FORMULATIONS AND METHODS FOR THEIR USE IN TREATING NEUROPATHOLOGY AND NEURODEGENERATION CAUSED BY TRAUMATIC INJURY - Novel two-component formulations, procedures and methods for use in treating neuropathology and neurodegeneration incident to trauma are provided. Two-component formulations of the invention comprise biologically active forms of at least one neurosteroid or neuroactive steroid, such as progesterone or synthetic progestin, and at least one anti-epileptic or anticonvulsant, such as pregabalin. The provided formulations are configured or adapted to prevent or reduce the incidence and severity of neurological damage caused by trauma. Formulations, procedures and methods of the invention advantageously effect both neuroprotective actions to prevent or reduce secondary injuries, and neurotrophic actions to repair and restore cells and tissues affected by the trauma, and are especially useful in treating neurological trauma, such as those caused by sports injuries, chemical weapons, vehicle collisions and improvised explosive devices in combat. | 2014-07-10 |
20140194398 | Tanaproget Compositions Containing Ethinyl Estradiol - Compositions containing micronized tanaproget, or a pharmaceutically acceptable salt thereof, and ethinyl estradiol and methods of preparing the same are provided. Also provided are kits containing the compositions, methods of contraception and hormone replacement therapy including administering a composition containing micronized tanaproget and ethinyl estradiol. | 2014-07-10 |
20140194399 | USE OF PUFAS FOR TREATING SKIN INFLAMMATION - The present invention provides a compound which is a polyunsaturated fatty acid (PUFA) derivative of formula (I), | 2014-07-10 |
20140194400 | Nasal Pharmaceutical Formulation - The present invention relates to a nasel formulation comprising as its active ingredient an intranasal corticosteroid, and also to a method for prophylaxis or treatment of seasonal or perennial allergic and non-allergic rhinitis and rhinoconjunctivitis. | 2014-07-10 |
20140194401 | METHODS FOR REDUCING CELLULAR PROLIFERATION AND TREATING CERTAIN DISEASES - Disclosed herein are methods of treating cancer and/or reducing cellular proliferation in a patient, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein. | 2014-07-10 |
20140194402 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY - Described herein are methods for using compounds that activate pyruvate kinase. | 2014-07-10 |
20140194403 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS - Provided herein are methods for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal, which comprises administering to said mammal in need thereof a therapeutically effective amount of a compound of Formula I: | 2014-07-10 |
20140194404 | AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES - This invention relates to amidopyrazole compounds that are inhibitors of Interleukin receptor-associated kinases, in particular IRAK-4, and are useful in the treatment of cellular proliferative diseases, for example, cancer, hyperplasia, restenosis, cardiac hypertrophy, immune disorders and inflammation. | 2014-07-10 |
20140194405 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES - The disclosed compounds are useful in the treatment of mammalian cancers and especially human cancers. Compounds, pharmaceutical compositions, and methods of Formula I are disclosed: | 2014-07-10 |
20140194406 | ALKYNYL SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASES INHIBITORS - The present invention relates to alkynyl substituted pyrimidinyl-pyrrole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular Jak and/or Src family kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them. | 2014-07-10 |
20140194407 | NOVEL ANTIPLATELET AGENT - The present invention relates to a novel antiplatelet agent and a novel compound which is an active ingredient for the agent. The present invention provides the antiplatelet agent comprising a compound represented by the formula I: | 2014-07-10 |
20140194408 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS - Heteroaryl pyridone and aza-pyridone compounds of Formula I are provided, where one or two of X | 2014-07-10 |
20140194409 | Method of administration of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia - The present invention relates to 4-((1R,3S)-6-chloro-3-phenyl-indan-1yl)-1,2,2-trimethyl-piperazine and the salts thereof with activity at dopamine D | 2014-07-10 |
20140194410 | THIOLACTAMS AND USES THEREOF - This invention provides compounds of formula I: | 2014-07-10 |
20140194411 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF - The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are benzazepine compounds. These compounds are serotonin receptor (5-HT | 2014-07-10 |
20140194412 | THIOXOTHIAZOLIDINE DERIVATIVE HAVING RAS FUNCTION INHIBITORY EFFECT - The present invention provides an anticancer drug having a Ras function inhibitory action. | 2014-07-10 |
20140194413 | INHIBITORS OF BRUTON'S TYROSINE KINASE - This application discloses 5-phenyl-1H-pyridin-2-one and 6-phenyl-2H-pyridazin-3-one derivatives according to generic Formulae I-IV: | 2014-07-10 |
20140194414 | TETRACYCLIC COMPOUNDS - This disclosure relates to new tetracyclic compounds that may be used to modulate a histamine receptor in an individual. The compounds in one embodiment are tetracyclic[4,3-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 2014-07-10 |
20140194415 | FATTY ACID SYNTHASE INHIBITORS - This invention relates to spirocyclic piperidines according to Formula (I) and the use of spirocyclic piperidines for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of spirocyclic piperidines in the treatment of cancer. | 2014-07-10 |
20140194416 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS - The invention relates to N-hydroxylsulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxylsulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxylsulfonamide derivatives. | 2014-07-10 |
20140194417 | IRAK INHIBITORS AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same. | 2014-07-10 |
20140194418 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES - Compounds of formula (I) or pharmaceutical acceptable salts are provided, wherein X | 2014-07-10 |
20140194419 | CHROMENONE DERIVATIVES - The invention concerns chromenone derivatives of Formula I | 2014-07-10 |
20140194420 | AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY - Disclosed is a compound which is useful as an AMPK activator. | 2014-07-10 |
20140194421 | HETEROCYCLIC GLUTAMINASE INHIBITORS - The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention. | 2014-07-10 |
20140194422 | PIPERAZINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO - The disclosure relates to piperazine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to inhibitors of NADPH-oxidase. | 2014-07-10 |
20140194423 | COMBINATION PRODUCTS - The invention concerns the combinations of an mGluR modulator, e.g. an mGluR5 modulator and at least one of L-dopa, a dopamine modulator, e.g. a dopamine agonist, a dopa decarboxylase inhibitor or a catechol-O-methyl transferase inhibitor. | 2014-07-10 |
20140194424 | SPIROLACTAM DERIVATIVES AND USES OF SAME - The present invention provides spirolactam derivatives of formula (I): | 2014-07-10 |
20140194425 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents - The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same. | 2014-07-10 |
20140194426 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS - In one aspect, the invention relates to compounds having the formula: | 2014-07-10 |
20140194427 | Deuterium Substituted Fumarate Derivatives - Provided is a compound of formula (I): | 2014-07-10 |
20140194428 | Combination treatments for bipolar disorders - The invention relates generally to novel compositions and methods comprising a scyllo-inositol compound and one or both of valproic acid compound and lamotrigine. The compositions and methods provide beneficial effects in the treatment of bipolar disorders. | 2014-07-10 |
20140194429 | COMPOSITIONS FOR TREATMENT OF CANCER - Compounds that are specifically toxic to cancer stem cells are disclosed. | 2014-07-10 |